Search

Your search keyword '"Kidney diseases -- Drug therapy"' showing total 736 results
Start Over Descriptor "Kidney diseases -- Drug therapy"
736 results on '"Kidney diseases -- Drug therapy"'

1. A Mathematical Model of Glomerular Fibrosis in Diabetic Kidney Disease to Predict Therapeutic Efficacy (Updated August 13, 2024)

Subjects
Medical research -- Analysis -- Health aspects, Medicine, Experimental -- Analysis -- Health aspects, Fibrosis -- Drug therapy, Diseases -- Drug therapy, Kidney diseases -- Drug therapy, Physical fitness -- Analysis -- Health aspects, Health
Abstract

2024 AUG 31 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

Published
2024

2. Fabhalta Granted Accelerated Approval for Immunoglobulin A Nephropathy

Author

Ernst, Diana

Subjects
United States. Food and Drug Administration, Immunoglobulin A, Drug approval, Kidney diseases -- Drug therapy, Health, Fabhalta (Medication)
Abstract

The Food and Drug Administration (FDA) has granted accelerated approval to Fabhalta[sup.®] (iptacopan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, [...]

Published
2024

3. Velphoro Approved for Pediatric Patients With Hyperphosphatemia in CKD

Author

Park, Brian

Subjects
Pediatrics, Children -- Health aspects, Kidney diseases -- Drug therapy, Health, Velphoro (Medication)
Abstract

The Food and Drug Administration (FDA) has expanded the approval of https://www.empr.com/drug/velphoro/ (sucroferric oxyhydroxide) to include control of serum phosphorus levels in pediatric patients 9 years of age and older [...]

Published
2024

4. 23andMe Inc. Researchers Have Published New Data on Hypertension (Discovery of RXFP2 genetic association in resistant hypertensive men and RXFP2 antagonists for the treatment of resistant hypertension)

Subjects
Genetic research, Kidney diseases -- Drug therapy, Physical fitness, Hypertension -- Drug therapy, Health
Abstract

2024 JUN 29 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New study results on hypertension have been published. According to news originating [...]

Published
2024

5. New Obesity Study Findings Have Been Reported by Investigators at National Institute for Diabetes and Digestive and Kidney Diseases (Approach To Obesity Treatment In Primary Care a Review)

Subjects
Medical research -- Reports, Medicine, Experimental -- Reports, Obesity -- Drug therapy, Diabetes therapy -- Reports, Chronic diseases -- Drug therapy, Kidney diseases -- Drug therapy, Weight loss -- Drug therapy, Physical fitness -- Reports, Health
Abstract

2024 JUN 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on Nutritional and Metabolic Diseases and Conditions - Obesity is [...]

Published
2024

6. Atacicept Gets Breakthrough Therapy Status for Immunoglobulin A Nephropathy

Author

Park, Brian

Subjects
United States. Food and Drug Administration, Immunoglobulin A, Kidney diseases -- Drug therapy, Health
Abstract

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to atacicept for the treatment of immunoglobulin A nephropathy (IgAN). The designation is supported by data from the phase [...]

Published
2024

7. Researchers at University of Pittsburgh Report New Data on Cancer (Impact of the 2021 Ckd-epi Equation On Anticancer Pharmacotherapy In Black and Non-black Cancer Patients)

Subjects
United States. National Institutes of Health -- Reports, Oncology, Experimental -- Reports, Cancer patients -- Drug therapy, Cancer -- Research, Kidney diseases -- Drug therapy, Physical fitness -- Reports, Health
Abstract

2024 APR 27 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on Cancer is the subject of a report. According to [...]

Published
2024

8. Delayed Anemia Treatment Ups Cardiovascular Events Risks in CKD

Author

Persaud, Natasha

Subjects
Mitsubishi Tanabe Pharma Corp., Heart attack -- Drug therapy, Anemia -- Drug therapy, Kidney diseases -- Drug therapy, Health
Abstract

Delaying renal anemia treatment with long-acting erythropoiesis-stimulating agents (ESAs) until hemoglobin levels fall below 9.0 g/dL increases the risks for cardiovascular events among patients with anemia and nondialysis-dependent chronic kidney [...]

Published
2024

9. Former Chinook team launches Borealis Biosciences with $150-million from Novartis, Versant

Author

Silcoff, Sean

Subjects
Novartis AG -- Alliances and partnerships -- Investments -- Organization formation, Versant Ventures -- Alliances and partnerships -- Investments -- Organization formation, Biotechnology industry -- Names -- Organization formation -- Finance -- Product development, Gene therapy -- Product development -- Finance, Kidney diseases -- Drug therapy, Venture capital companies -- Alliances and partnerships -- Investments -- Organization formation, Pharmaceutical industry -- Alliances and partnerships -- Investments -- Organization formation, Company financing, Company investment, General interest, News, opinion and commentary
Abstract

Byline: SEAN SILCOFF; Staff The group behind one of the biggest takeovers in Canadian biotech has teamed up again to launch the latest addition to Vancouver's teeming life-sciences sector. San [...]

Published
2024

10. Researchers from Showa University Provide Details of New Studies and Findings in the Area of Acute Kidney Injury (Self-controlled Case Series Study for Acute Kidney Injury After Starting Proton Pump Inhibitors or Potassium-competitive Acid ...)

Subjects
Oncology, Experimental, Cancer -- Research, Proton pump inhibitors, Kidney diseases -- Drug therapy, Physical fitness, Health
Abstract

2024 MAR 30 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Kidney Diseases and Conditions - Acute Kidney [...]

Published
2024

12. Initial eGFR Decline Predicts Tolvaptan Efficacy in ADPKD

Author

Persaud, Natasha

Subjects
Kidney diseases -- Drug therapy, Health
Abstract

Initial declines in estimated glomerular filtration rate (eGFR) after tolvaptan administration predict the drug’s effectiveness in slowing future eGFR decline in patients with autosomal dominant polycystic kidney disease (ADPKD), investigators [...]

Published
2024

13. Sibeprenlimab Designated Breakthrough Therapy for IgA Nephropathy

Author

Ernst, Diana

Subjects
United States. Food and Drug Administration, Immunoglobulin A, Kidney diseases -- Drug therapy, Health
Abstract

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN). Sibeprenlimab is a humanized IgG2 monoclonal antibody that reduces [...]

Published
2024

14. Research from Southern Medical University Broadens Understanding of Biomedicine and Pharmacotherapy (Targeting ROCK1 in diabetic kidney disease: Unraveling mesangial fibrosis mechanisms and introducing myricetin as a novel antagonist)

Subjects
Molecular dynamics, Fibrosis -- Drug therapy, Medical colleges, Kidney diseases -- Drug therapy, Physical fitness, Health
Abstract

2024 FEB 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on biomedicine and pharmacotherapy have been presented. According to news [...]

Published
2024

15. Sibeprenlimab Shows Promise for IgA Nephropathy

Author

Persaud, Natasha

Subjects
Immunoglobulin A, Kidney diseases -- Drug therapy, Health
Abstract

Sibeprenlimab significantly reduces proteinuria in patients with high-risk IgA nephropathy (IgAN), according to trial results published in The New England Journal of Medicine. In the international phase 2, double-blind ENVISION [...]

Published
2024

16. GLP-1 DRUG LIRAGLUTIDE MAY PROTECT AGAINST DEMENTIA

Subjects
Infection control, Heart diseases -- Drug therapy, Medical research, Medicine, Experimental, Diabetes therapy, Alzheimer's disease -- Drug therapy, Liraglutide, Kidney diseases -- Drug therapy, Weight loss -- Drug therapy, Business, News, opinion and commentary
Abstract

Key Takeaways A GLP-1 agonist - the class of drugs shown to help with diabetes and weight loss and reduce the risk of heart disease - also may protect the [...]

Published
2024

17. Polycystic Kidney Diseases Drug Pipeline Research 2024: Innovative Drug Therapies to Transform Treatment Landscape

Subjects
Medical research -- Forecasts and trends, Medicine, Experimental -- Forecasts and trends, Diseases -- Drug therapy, Kidney diseases -- Drug therapy, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

Dublin: Research and Markets has issued the following news release: The 'Polycystic Kidney Disease - Pipeline Insight, 2024' report has been added to ResearchAndMarkets.com's offering. The global healthcare community is [...]

Published
2024

18. Alebund Reports Update for AP306 EOS789, a First-in-Class Pan-inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis

Subjects
Chugai Pharmaceutical Company Ltd. -- Product development, Sevelamer carbonate, Medical research, Medicine, Experimental, Phosphorus imbalance -- Drug therapy, Carbonates -- Product development, Clinical trials, Hemodialysis, Phosphates -- Product development, Kidney diseases -- Drug therapy, Physical fitness, Pharmaceutical industry -- Product development, Health
Abstract

2023 DEC 30 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Alebund Pharmaceuticals ('Alebund' or the 'Company'), an integrated biopharmaceutical company focusing on [...]

Published
2023

19. Taiwan FDA accepts Everest Medicines' NDA for Nefecon to treat primary IgA nephropathy in adult patients

Subjects
Immunoglobulin A, Drugs -- Product development, Vaccines -- Product development, Kidney diseases -- Drug therapy, Pharmaceuticals and cosmetics industries
Abstract

Byline: Shanghai Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced that its New Drug Application (NDA) for Nefecon has been [...]

Published
2023

20. South Korean's MFDS accepts Everest Medicines' NDA for Nefecon to treat primary IgA nephropathy in adult patients

Subjects
Immunoglobulin A, Drugs -- Product development, Vaccines -- Product development, Kidney diseases -- Drug therapy, Pharmaceuticals and cosmetics industries
Abstract

Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced that its New Drug Application (NDA) for Nefecon has been accepted for [...]

Published
2023

21. New Findings from Department of Internal Medicine in the Area of Obesity and Diabetes Reported (Are You Aware 'asthmatic Nephropathy'? Metabolic and Renal Parameters In Newly Diagnosed Untreated Asthmatic Patients Without Diabetes)

Subjects
Women -- Health aspects, Medical research, Medicine, Experimental, Insulin resistance -- Drug therapy, Body mass index, Kidney diseases -- Drug therapy, Asthma -- Drug therapy, Health, Women's issues/gender studies
Abstract

2023 NOV 30 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Nutritional and Metabolic Diseases and Conditions - Obesity and Diabetes [...]

Published
2023

22. Researchers at Albert Einstein College of Medicine Report New Data on Heart Failure (Ketone Bodies Rescue Mitochondrial Dysfunction Via Epigenetic Remodeling)

Subjects
United States. National Heart, Lung and Blood Institute -- Reports, Epigenetic inheritance -- Reports, Kidney diseases -- Drug therapy, Physical fitness -- Reports, Heart failure -- Drug therapy, Health
Abstract

2023 NOV 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Heart Disorders and Diseases - Heart Failure. [...]

Published
2023

24. Felzartamab Gets Breakthrough Therapy Status for Primary Membranous Nephropathy

Author

Park, Brian

Subjects
United States. Food and Drug Administration, Autoimmunity, Autoantibodies, Drug approval, Kidney diseases -- Drug therapy, Health
Abstract

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to felzartamab for the treatment of primary membranous nephropathy (PMN), a rare autoantibody-mediated autoimmune kidney disease. There are currently [...]

Published
2023

25. Pharmaceutical Administration Bureau of Macau approves Everest Medicines' NDA for Nefecon for primary IgA nephropathy treatment

Subjects
Immunoglobulin A, Drug approval, Vaccines -- Product development, Kidney diseases -- Drug therapy, Pharmaceuticals and cosmetics industries
Abstract

Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced that the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China, [...]

Published
2023

26. Omeros Ends Trial Evaluating Narsoplimab for IgA Nephropathy

Author

Ernst, Diana

Subjects
Immunoglobulin A, Kidney diseases -- Drug therapy, Health
Abstract

Omeros is discontinuing its phase 3 trial evaluating narsoplimab for the treatment of immunoglobulin A (IgA) nephropathy as the study did not meet its primary endpoint. The double-blind, randomized, placebo-controlled [...]

Published
2023

27. Bispecific CD19/CD20 CAR T-Cell Therapy Fast Tracked for SLE, Lupus Nephritis

Author

Ernst, Diana

Subjects
T cells, Lupus -- Drug therapy, Clinical trials, Kidney diseases -- Drug therapy, Health
Abstract

The Food and Drug Administration (FDA) has granted Fast Track designation to IMPT-514, a bispecific CD19/CD20-targeting chimeric antigen receptor (CAR) T-cell therapy for the treatment of active refractory https://www.empr.com/home/news/lupus-nephritis-treatment-consensus-and-future-directions/ (LN) [...]

Published
2023

28. Study Findings from Institute of Medicine Tribhuvan University Broaden Understanding of Lupus (Full-house nephropathy in antinuclear antibody-negative systemic lupus erythematosus: A case report)

Subjects
Lupus -- Drug therapy, Autoantibodies, Systemic lupus erythematosus -- Drug therapy, Kidney diseases -- Drug therapy, Health
Abstract

2024 SEP 13 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New study results on lupus have been published. According to news reporting out [...]

Published
2024

29. Data on Acute Kidney Injury Reported by Researchers at Institute for Cancer Research and Treatment (IRCCS) San Raffaele Scientific Institute (The Renal Effects of Amino Acids Infusion)

Subjects
Oncology, Experimental, Amino acids, Cancer -- Drug therapy -- Research, Kidney diseases -- Drug therapy, Health
Abstract

2024 AUG 9 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on Kidney Diseases and Conditions - Acute Kidney Injury is the [...]

Published
2024

30. DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

Subjects
Stroke (Disease) -- Drug therapy, Ischemia -- Drug therapy, Clinical trials, Kidney diseases -- Drug therapy, Business, Business, international
Abstract

MINNEAPOLIS -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in [...]

Published
2024

31. Long-Term Data Confirm Benefit of Sparsentan in IgA Nephropathy

Author

Duffy, Steve

Subjects
Medical research, Medicine, Experimental, Immunoglobulin A, Kidney diseases -- Drug therapy, Health
Abstract

Results from a confirmatory study evaluating sparsentan in patients with primary immunoglobulin A nephropathy (IgAN) showed that the treatment was associated with kidney function preservation when compared with irbesartan. In [...]

Published
2023

33. Functional tests to guide management in an adult with loss of function of type-1 angiotensin II receptor

Author

Viering, Daan H. H. M., Bech, Anneke P., de Baaij, Jeroen H. F., Steenbergen, Eric J., Danser, A. H. Jan, Wetzels, Jack F. M., and Bindels, René J. M.

Subjects
Angiotensin II receptor blockers, Renin-angiotensin system -- Methods, Fludrocortisone -- Health aspects, Kidney diseases -- Drug therapy, Health
Abstract

Background Genetic loss of function of AGT (angiotensinogen), REN (renin), ACE (angiotensin-converting enzyme), or AGTR1 (type-1 angiotensin II receptor) leads to renal tubular dysgenesis (RTD). This syndrome is almost invariably lethal. Most surviving patients reach stage 5 chronic kidney disease at a young age. Methods Here, we report a 28-year-old male with a homozygous truncating mutation in AGTR1 (p.Arg216*), who survived the perinatal period with a mildly impaired kidney function. In contrast to classic RTD, kidney biopsy showed proximal tubules that were mostly normal. During the subsequent three decades, we observed evidence of both tubular dysfunction (hyperkalemia, metabolic acidosis, salt-wasting and a urinary concentrating defect) and glomerular dysfunction (reduced glomerular filtration rate, currently ~30 mL/min/1.73 m.sup.2, accompanied by proteinuria). To investigate the recurrent and severe hyperkalemia, we performed a patient-tailored functional test and showed that high doses of fludrocortisone induced renal potassium excretion by 155%. Furthermore, fludrocortisone lowered renal sodium excretion by 39%, which would have a mitigating effect on salt-wasting. In addition, urinary pH decreased in response to fludrocortisone. Opposite effects on urinary potassium and pH occurred with administration of amiloride, further supporting the notion that a collecting duct is present and able to react to fludrocortisone. Conclusions This report provides living proof that even truncating loss-of-function mutations in AGTR1 are compatible with life and relatively good GFR and provides evidence for the prescription of fludrocortisone to treat hyperkalemia and salt-wasting in such patients., Author(s): Daan H. H. M. Viering [sup.1] , Anneke P. Bech [sup.2] , Jeroen H. F. de Baaij [sup.1] , Eric J. Steenbergen [sup.3] , A. H. Jan Danser [sup.4] [...]

Published
2021
Full Text
View/download PDF

34. Researcher from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Reports Details of New Studies and Findings in the Area of Drugs and Therapies (Single-Cell Transcriptional Signatures of Glomerular Disease in Transgenic ...)

Subjects
United States. National Institute of Diabetes and Digestive and Kidney Diseases -- Analysis -- Reports, Oncology, Experimental -- Reports -- Analysis, Diseases -- Drug therapy -- Maryland, Drugs -- Reports -- Analysis, Genetic engineering -- Reports -- Analysis, Genetic transcription -- Analysis -- Reports, Cancer -- Research, Kidney diseases -- Drug therapy, Health
Abstract

2024 MAY 20 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Research findings on drugs and therapies are discussed in a new report. According to news [...]

Published
2024

35. Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion

Subjects
United States. Food and Drug Administration, Medical research, Medicine, Experimental, Lupus -- Drug therapy, Systemic lupus erythematosus -- Drug therapy, Kidney diseases -- Drug therapy, Business, Business, international
Abstract

SYNCAR-001 + STK-009 combination will be studied in two distinct lupus patient populations: non-renal systemic lupus erythematosus (SLE) and lupus nephritis (LN) MENLO PARK, Calif. -- Synthekine Inc., an engineered [...]

Published
2024

36. Atara Biotherapeutics Unveils Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Subjects
United States. Food and Drug Administration, Lupus -- Drug therapy, Systemic lupus erythematosus -- Drug therapy, B cells, Kidney diseases -- Drug therapy, General interest, News, opinion and commentary
Abstract

THOUSAND OAKS: Atara Biotherapeutics, Inc. announces its recent submission of an Investigational New Drug application to the U.S. Food and Drug Administration for the use of ATA3219 as a monotherapy [...]

Published
2024

37. US FDA grants orphan drug designation to HI-Bio's felzartamab to treat membranous nephropathy

Subjects
United States. Food and Drug Administration, Autoimmunity, Orphan drugs, Monoclonal antibodies, Kidney diseases -- Drug therapy, Pharmaceuticals and cosmetics industries
Abstract

Human Immunology Biosciences (HI-Bio), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), announced that the US Food and Drug Administration (FDA) has granted orphan [...]

Published
2023

38. Reports Outline Insulin Resistance Findings from Chiang Mai University (Metformin Mitigates Renal Dysfunction In Obese Insulin-resistant Rats Via Activation of the Ampk/ppar Alpha Pathway)

Subjects
Obesity -- Drug therapy, Insulin resistance -- Drug therapy, Metformin -- Testing, Protein kinases -- Health aspects, Cellular signal transduction -- Research, Pharmaceutical research, Kidney diseases -- Drug therapy, Health
Abstract

2023 MAY 6 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on Endocrine System Diseases and Conditions - Insulin Resistance is [...]

Published
2023

39. Metformin Use Associated With Better Kidney Graft Survival

Author

Persaud, Natasha

Subjects
Kidneys -- Transplantation, Diabetes -- Drug therapy, Metformin -- Reports, Kidney diseases -- Drug therapy, Organ transplant recipients -- Drug therapy, Health
Abstract

Metformin may prolong graft survival in kidney transplant recipients (KTRs) with diabetes mellitus, new study findings suggest. In a retrospective study of 1995 KTRs with diabetes from 6 Korean centers, [...]

Published
2023
Full Text
View/download PDF

40. Findings from Gilead Sciences Inc. Reveals New Findings on Acyl Coenzyme A (Effect of Renal Impairment On the Pharmacokinetics of Firsocostat, an Acetyl-coenzyme a Carboxylase Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X ...)

Subjects
Agonists (Biochemistry) -- Chemical properties -- Dosage and administration, Pharmacokinetics -- Research, Pharmacology, Experimental, Enzyme inhibitors -- Chemical properties -- Dosage and administration, Kidney diseases -- Drug therapy, Health
Abstract

2023 APR 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Enzymes and Coenzymes - Acyl Coenzyme A is [...]

Published
2023

41. Department of Internal Medicine Researcher Describes Advances in Cardiovascular Diseases and Conditions (The Effect of Aldosterone on Cardiorenal and Metabolic Systems)

Subjects
Medical research, Medicine, Experimental, Corticosteroids, Aldosterone, Kidney diseases -- Drug therapy, Physical fitness, Hypertension -- Drug therapy, Health
Abstract

2023 APR 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on cardiovascular diseases and conditions have been presented. According to [...]

Published
2023

42. Filspari Granted Accelerated Approval to Reduce Proteinuria in IgA Nephropathy

Author

Ernst, Diana

Subjects
United States. Food and Drug Administration, Proteinuria -- Drug therapy, Immunoglobulin A, Clinical trials, Drug approval, Kidney diseases -- Drug therapy, Health
Abstract

The Food and Drug Administration (FDA) has granted accelerated approval to Filspari[sup.™] (sparsentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, [...]

Published
2023

44. Researcher at National Institute of Diabetes and Digestive and Kidney Diseases Has Published New Data on Obesity (Approach to Obesity Treatment in Primary Care)

Subjects
United States. National Institute of Diabetes and Digestive and Kidney Diseases -- Reports, Medical research -- Reports, Medicine, Experimental -- Reports, Obesity -- Drug therapy, Chronic diseases -- Drug therapy, Kidney diseases -- Drug therapy, Weight loss -- Drug therapy, Health
Abstract

2024 MAR 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity & Diabetes Week -- Investigators publish new report on obesity. According to news originating from Bethesda, Maryland, [...]

Published
2024

45. Studies in the Area of Health and Medicine Reported from Institute for Cancer Research and Treatment (IRCCS) (Major Adverse Kidney Events in Pediatric Continuous Kidney Replacement Therapy)

Subjects
Oncology, Experimental -- Reports, Pediatrics -- Reports, Cancer -- Drug therapy -- Research, Kidney diseases -- Drug therapy, Health
Abstract

2024 MAR 15 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Research findings on agriculture are discussed in a new report. According to news [...]

Published
2024

46. Albert Einstein College of Medicine Reports Findings in Lupus (Novel Biomarker Discovery Through Comprehensive Proteomic Analysis of Lupus Mouse Serum)

Subjects
United States. National Institutes of Health -- Analysis -- Reports, Medical research -- Analysis -- Reports, Medicine, Experimental -- Analysis -- Reports, Lupus -- Drug therapy, Systemic lupus erythematosus -- Drug therapy, Kidney diseases -- Drug therapy, Health
Abstract

2024 FEB 2 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on Autoimmune Diseases and Conditions - Lupus is the subject of [...]

Published
2024

47. University of Colorado School of Medicine Researcher Furthers Understanding of Obesity and Diabetes (Insulin Secretion, Sensitivity, and Kidney Function in Young Individuals With Type 2 Diabetes)

Subjects
Insulin resistance -- Drug therapy, Insulin -- Reports, Medical colleges -- Reports, Type 2 diabetes -- Drug therapy, Kidney diseases -- Drug therapy, Health
Abstract

2024 JAN 15 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity & Diabetes Week -- Investigators publish new report on obesity and diabetes. According to news originating from [...]

Published
2024

48. Everest Medicines Announces New Drug Application Acceptance of Nefecon in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients

Subjects
Immunoglobulin A, Drugs, Vaccines, Kidney diseases -- Drug therapy, Business, News, opinion and commentary
Abstract

SHANGHAI, Dec. 26, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced [...]

Published
2023

49. Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan-inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis

Subjects
Chugai Pharmaceutical Company Ltd. -- Product development, Sevelamer carbonate, Medical research, Medicine, Experimental, Phosphorus imbalance -- Drug therapy, Carbonates -- Product development, Clinical trials, Hemodialysis, Phosphates -- Product development, Kidney diseases -- Drug therapy, General interest, News, opinion and commentary
Abstract

SHANGHAI: Alebund Pharmaceuticals has issued the following news release: Alebund Pharmaceuticals ('Alebund' or the 'Company'), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases [...]

Published
2023

50. Everest Medicines Announces Acceptance of Nefecon(r) New Drug Applications for the Treatment of Primary IgA Nephropathy in Adult Patients in South Korea

Subjects
Immunoglobulin A, Drugs, Vaccines, Kidney diseases -- Drug therapy, General interest, News, opinion and commentary
Abstract

SHANGHAI: Everest Medicines has issued the following news release: Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines [...]

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results